Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Fujian Green Pine
300132
5
Yili Chuanning Biotechnology
301301
(Q2)Apr 4, 2025 | (Q1)Jan 3, 2025 | (FY)Sep 30, 2024 | (Q4)Sep 30, 2024 | (Q3)Jun 28, 2024 | (Q2)Mar 29, 2024 | (Q1)Dec 29, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.25%212.9M | 199.8M | -9.22%811M | -9.54%205.7M | -9.95%209.1M | -9.64%206.2M | -7.59%190M | 3.96%893.4M | -1.73%227.4M | 8.25%232.2M |
Operating revenue | 3.25%212.9M | --199.8M | -9.22%811M | -9.54%205.7M | -9.95%209.1M | -9.64%206.2M | -7.59%190M | 3.96%893.4M | -1.73%227.4M | 8.25%232.2M |
Cost of revenue | -2.99%136.2M | 131.3M | -8.12%554.1M | -7.23%138.6M | -8.79%142.2M | -9.71%140.4M | -6.61%132.9M | 4.72%603.1M | -4.78%149.4M | 10.49%155.9M |
Gross profit | 16.57%76.7M | 68.5M | -11.51%256.9M | -13.97%67.1M | -12.32%66.9M | -9.49%65.8M | -9.79%57.1M | 2.40%290.3M | 4.70%78M | 3.95%76.3M |
Operating expense | -6.02%54.6M | 57.3M | 5.44%224.8M | 4.66%56.2M | 10.56%57.6M | 1.75%58.1M | 5.17%52.9M | 9.17%213.2M | 7.62%53.7M | 3.37%52.1M |
Selling and administrative expenses | -8.17%32.6M | --33.8M | 7.32%137.8M | 7.52%34.3M | 10.90%35.6M | 4.11%35.5M | 6.93%32.4M | 8.54%128.4M | 7.41%31.9M | 6.29%32.1M |
Research and development costs | -2.65%22M | --23.5M | 2.59%87M | 0.46%21.9M | 10.00%22M | -1.74%22.6M | 2.50%20.5M | 10.13%84.8M | 7.92%21.8M | -0.99%20M |
Operating profit | 187.01%22.1M | 11.2M | -58.37%32.1M | -55.14%10.9M | -61.57%9.3M | -50.64%7.7M | -67.69%4.2M | -12.59%77.1M | -1.22%24.3M | 5.22%24.2M |
Net non-operating interest income expense | -19.67%-7.3M | -5.9M | 10.55%-22.9M | -3.57%-5.8M | 12.50%-5.6M | 7.58%-6.1M | 22.86%-5.4M | 35.03%-25.6M | 39.13%-5.6M | 31.18%-6.4M |
Non-operating interest income | 61.11%2.9M | --2.1M | 97.30%7.3M | 12.50%1.8M | 100.00%1.8M | 157.14%1.8M | 280.00%1.9M | 825.00%3.7M | 700.00%1.6M | 800.00%900K |
Non-operating interest expense | 40.30%9.4M | --7.1M | 0.37%26.8M | 6.15%6.9M | -1.49%6.6M | 1.52%6.7M | -4.35%6.6M | -26.65%26.7M | -26.14%6.5M | -24.72%6.7M |
Total other finance cost | -33.33%800K | --900K | 30.77%3.4M | 0.00%700K | 33.33%800K | 71.43%1.2M | 16.67%700K | -23.53%2.6M | 16.67%700K | 20.00%600K |
Other net income (expense) | -671.43%-4M | -2.8M | 79.21%-4.2M | 85.31%-2.6M | -314.29%-2.9M | 158.33%700K | 200.00%600K | -369.77%-20.2M | -1,261.54%-17.7M | -250.00%-700K |
Gain on sale of security | ---- | ---- | -130.00%-2.3M | ---- | ---- | ---- | ---- | 33.33%-1M | ---- | ---- |
Earnings from equity interest | ---- | ---- | 28.57%-1M | ---- | ---- | ---- | ---- | 53.33%-1.4M | ---- | ---- |
Special income (charges) | ---- | ---- | 112.80%2.1M | ---- | ---- | ---- | ---- | ---16.4M | ---- | ---- |
-Less:Restructuring and merger&acquisition | ---- | ---- | ---2.1M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
-Write off | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --16.4M | ---- | ---- |
Other non- operating income (expenses) | -671.43%-4M | ---2.8M | -114.29%-3M | -227.27%-1.4M | -314.29%-2.9M | 158.33%700K | 200.00%600K | -800.00%-1.4M | -65.63%1.1M | -250.00%-700K |
Income before tax | 369.57%10.8M | 2.5M | -84.03%5M | 150.00%2.5M | -95.32%800K | -70.51%2.3M | -111.11%-600K | -29.66%31.3M | -92.91%1M | 26.67%17.1M |
Income tax | 428.57%3.7M | 2.6M | 400.00%52.2M | 269.03%52.4M | -108.86%-700K | -80.00%700K | -109.09%-200K | -227.01%-17.4M | -3,544.44%-31M | 54.90%7.9M |
Net income | 343.75%7.1M | -100K | -196.92%-47.2M | -255.94%-49.9M | -83.70%1.5M | -62.79%1.6M | -112.50%-400K | 58.12%48.7M | 142.42%32M | 9.52%9.2M |
Net income continuous Operations | 343.75%7.1M | ---100K | -196.92%-47.2M | -255.94%-49.9M | -83.70%1.5M | -62.79%1.6M | -112.50%-400K | 58.12%48.7M | 142.42%32M | 9.52%9.2M |
Minority interest income | 0.00%200K | 200K | 0.00%500K | 0.00%100K | 0.00%100K | 0.00%200K | 0.00%100K | 0.00%500K | 0.00%100K | -50.00%100K |
Net income attributable to the parent company | 392.86%6.9M | -300K | -198.96%-47.7M | -256.74%-50M | -84.62%1.4M | -65.85%1.4M | -116.13%-500K | 59.08%48.2M | 143.51%31.9M | 10.98%9.1M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 392.86%6.9M | -300K | -198.96%-47.7M | -256.74%-50M | -84.62%1.4M | -65.85%1.4M | -116.13%-500K | 59.08%48.2M | 143.51%31.9M | 10.98%9.1M |
Basic earnings per share | 466.67%0.17 | -0.01 | -197.50%-1.17 | -254.43%-1.22 | -86.96%0.03 | -70.00%0.03 | -112.50%-0.01 | 57.89%1.2 | 139.39%0.79 | 9.52%0.23 |
Diluted earnings per share | 466.67%0.17 | -0.01 | -208.33%-1.17 | -284.85%-1.22 | -85.71%0.03 | -70.00%0.03 | -112.50%-0.01 | 47.95%1.08 | 106.25%0.66 | 5.00%0.21 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |